Tailor-Made vaccine takes on melanoma in early trial
NCT ID NCT04930783
First seen Mar 28, 2026 · Last updated Jun 16, 2026 · Updated 14 times
Summary
This early-phase study tests a personalized vaccine (NeoVax) made from each patient's unique tumor mutations, combined with an immune-boosting drug (CDX-301) and standard immunotherapy (nivolumab or pembrolizumab). The goal is to see if this combination is safe and tolerable for people with advanced melanoma. Only 10 participants are enrolled, and the main focus is on side effects and finding the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.